On Friday, Shares of Cypress Semiconductor Corporation (NASDAQ:CY), lost -3.91% to $11.80, after the chipmaker made its “best and final” offer to acquire Integrated Silicon Solution (ISSI), which failed to beat Chinese investment firm Uphill Investment’s bid for the competitor chipmaker.
Cypress offered to buy Integrated Silicon for $22.60 a share with an additional fee of 10 cents a share added for every three months until the potential transaction gains regulatory approval, according to the Associated Press. The additional fee would start accruing on October 1 and enhance to a maximum of 20 cents a share.
Integrated Silicon said that Cypress’ offer was below Uphill Investment’s offer of $23 a share. The company will hold a special shareholder meeting on June 29 to approve Uphill’s acquisition offer.
The Integrated Silicon and Uphill deal is predictable to close in the third quarter of 2015.
Cypress Semiconductor Corporation provides mixed-signal programmable solutions, semiconductor memories, and integrated semiconductor solutions worldwide. The company’s Memory Products division designs and manufactures static random access memory (SRAM) products and nonvolatile RAMs used to store and retrieve data in networking, wireless infrastructure and handsets, computation, consumer, automotive, industrial, and other electronic systems; and general-purpose programmable clocks.
Shares of Cytori Therapeutics, Inc. (NASDAQ:CYTX), declined -5.48% to $0.59, during its last trading session.
Cytori Therapeutics, declared that enrollment has been accomplished in its US Phase IIb Osteoarthritis trial. The ACT-OA trial is a double-blind randomized, placebo-controlled trial evaluating the safety, feasibility and dosing of intra-articular administration of Cytori’s ECCO-50 cellular therapeutic in patients with knee osteoarthritis. A total of 94 patients were enrolled as of June 12, 2015.
The availability of safety and efficacy data in Q1 2016 will lead to informed decisions and discussions with the FDA regarding the study design and size of an osteoarthritis Phase III program with Cytori Cell Therapy.
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
Finally, American Airlines Group Inc. (NASDAQ:AAL), ended its last trade with -1.89% loss, and closed at $41.44.
American Airlines Group, applauds Friday’s decision by the U.S. Supreme Court to extend full marriage rights to same-sex couples in the United States, regardless of the state in which they reside.
“This is a historic moment for our country and for many of American’s employees,” said American’s Chairman and CEO Doug Parker. “Today’s decision reaffirms the commitment of companies like American that recognize equality is good for business and society as a whole.”
Earlier this year, American joined a broad coalition of U.S. corporations to support marriage equality in an amicus brief filed in the U.S. Supreme Court. American also joined dozens of large companies to pledge that “Equality is Our Business,” signing a public statement led by the Human Rights Campaign (HRC) seeking to get businesses and organizations to stand up for diversity.
American Airlines Group Inc., through its auxiliaries, operates in the airline industry. As of December 31, 2014, the company operated 983 mainline jets, in addition to 566 regional aircrafts through regional airline auxiliaries and third-party regional carriers.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
